Novo Nordisk's experimental diabetes drug UBT251 showed strong Phase II trial results, outperforming semaglutide in blood sugar and weight loss reduction. However, analysts from Deutsche Bank and Citi gave neutral ratings, noting the data is encouraging but not transformative. The drug, targeting three hormonal pathways, is positioned to compete with Eli Lilly's Mounjaro and retatrutide. Market impact will become clearer after mid-2026 obesity trial results and competition from oral weight-loss drugs like Wegovy and Lilly's upcoming treatments.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
